EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 2%

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shot up 2% on Tuesday . The company traded as high as $21.72 and last traded at $21.71. 27,523 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 944,644 shares. The stock had previously closed at $21.28.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on EYPT. Mizuho upped their price target on EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Capital One Financial reaffirmed an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. HC Wainwright reduced their price target on EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, January 16th. Finally, JPMorgan Chase & Co. began coverage on EyePoint Pharmaceuticals in a report on Monday, January 22nd. They issued an “overweight” rating and a $35.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.86.

EyePoint Pharmaceuticals Trading Down 4.1 %

The company has a 50 day simple moving average of $24.14 and a 200 day simple moving average of $18.27.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative return on equity of 61.48% and a negative net margin of 153.84%. The company had revenue of $14.03 million during the quarter, compared to analyst estimates of $8.71 million. During the same period in the previous year, the business earned ($0.61) EPS. As a group, equities analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -1.73 earnings per share for the current year.

Insider Activity

In other news, insider Dario A. Paggiarino sold 49,325 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $25.66, for a total value of $1,265,679.50. Following the completion of the sale, the insider now directly owns 36,505 shares in the company, valued at $936,718.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Dario A. Paggiarino sold 49,325 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $25.66, for a total value of $1,265,679.50. Following the completion of the sale, the insider now directly owns 36,505 shares in the company, valued at $936,718.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dario A. Paggiarino sold 5,135 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $25.00, for a total value of $128,375.00. Following the completion of the sale, the insider now owns 36,505 shares of the company’s stock, valued at $912,625. The disclosure for this sale can be found here. Insiders sold 56,169 shares of company stock worth $1,437,509 over the last ninety days. Corporate insiders own 13.05% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in EyePoint Pharmaceuticals by 533.4% in the fourth quarter. Barclays PLC now owns 7,005 shares of the company’s stock valued at $25,000 after acquiring an additional 5,899 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in EyePoint Pharmaceuticals in the fourth quarter valued at approximately $27,000. Toth Financial Advisory Corp lifted its holdings in EyePoint Pharmaceuticals by 250.0% in the third quarter. Toth Financial Advisory Corp now owns 3,500 shares of the company’s stock valued at $28,000 after acquiring an additional 2,500 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in EyePoint Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Tower Research Capital LLC TRC lifted its holdings in EyePoint Pharmaceuticals by 99.3% in the third quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $37,000 after acquiring an additional 2,294 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.